JAK3 inhibitors have become a buzzword in pharmaceuticals, with significant implications for treating various diseases, including autoimmune disorders and cancers. JAK (Janus Kinase) inhibitors, ...

A symposium at the American Academy of Dermatology 2023 Annual Meeting convened speakers who presented current data on the use of Janus kinase (JAK) inhibitors in dermatology, including in atopic ...

A meta-analysis showed no significant differences between JAK inhibitor use and TNF antagonist use in terms of the risk for serious infections or malignant neoplasms in patients with immune-mediated ...

A panel held at Fall Clinical Dermatology 2023 emphasized the role of Janus kinase (JAK) inhibitors in several skin conditions and highlighted new therapies in the space. Fall Clinical Dermatology ...

Checkpoint inhibitor therapies can be thought of as the molecular "brake release" for the immune system. These drugs eliminate the protein barriers that impede the immune system from recognizing and ...

Lynk’s zemprocitinib commercial partner, Simcere, will now continue the JAK inhibitor’s development across China in RA.

Higher doses of a novel Janus kinase inhibitor were associated with improved response over 24 weeks in a cohort of patients with alopecia areata, according to a study. Brett King, MD, PhD, of the ...

Inflammatory cytokines play a major role in the pathogenesis of immune-mediated chronic inflammatory diseases. Cytokines are rarely produced alone and play their role in a complex network with others.